Atropine sulphate 1% eye drops 5 ml.
- $3.00
Out Of Stock
The instruction for medical use
of ATROPINI SULFAS medicine
the Trade name
Atropini sulfas
the International unlicensed
name Atropini Sulfas Dosage Form
Eye drops 10mg/ml
Structure
of 1 ml of solution contains
active agent - Atropini sulfas of 0.05 g,
excipients: sodium chloride, sodium metabisulphite, water for injections.
The description
Colourless transparent liquid
Pharmacotherapeutic group
Drugs for treatment of diseases of eyes. Midriatiki. Holinoblokatora.
ATCS01FA01 code
Pharmacological
Pharmacokinetics properties.
Considering system influence of atropine when swallowing the eye drops which got via the plaintive channel into a nasopharynx, drug is easily soaked up in digestive tract, the bioavailability of drug is 50%, elimination half-life – 13 - 38 h, atropine for 50% contacts proteins of blood plasma, is metabolized in a liver, excreted by kidneys for 50% in not changed look.
The pharmacodynamics
Atropini sulfas reduces secretion of salivary and other glands, causes tachycardia, improves atrioventricular conductivity, reduces a tone of smooth muscle bodies, is expressed expands pupils (at the same time increase in intraocular pressure is possible), causes accommodation paralysis.
The mechanism of action is caused by selective blockade by m-holinoretseptorov atropine (to a lesser extent influences N-holinoretseptory) therefore the last become insensitive to acetylcholine which is formed in the field of the terminations of postganglionic parasympathetic nerves. The maximum mydriasis comes in 30 - 40 min. and remains within 7 - 10 days, accommodation paralysis respectively in 1 - 3 h and remains 8 - 12 days.
The system effect of atropine is caused by its anticholinergic (cholinolytic) action and includes oppression of secretion salivary, gastric, bronchial, sweat glands, a pancreas, increase of warm reductions (the braking action of n.vagus decreases by heart), decrease in a tone of smooth muscle bodies (a bronchial tree, abdominal organs, etc.).
Getting through a blood-brain barrier, atropine influences the central nervous system. Drug reduces a muscle tone and a tremor at patients with parkinsonism (central cholinolytic action), atropine excites a respiratory center in therapeutic doses, high doses of atropine cause motive and mental disturbances, spasms, the hallucinatory phenomena, breath paralysis.
Indications
- diagnostic mydriasis for an eyeground research
- for achievement of paralysis of accommodation for the purpose of definition of a true refraction of an eye
- as a part of complex therapy in inflammatory diseases, injuries of an eye, an embolism or a spasm of the central artery of a retina
the Route of administration and doses
With the medical purpose to adults and children are more senior than 7 years appoint on 1 - 2 drop of atropine 2 – 3 times a day.
After instillation atropine in a conjunctival cavity it is necessary to press immediately lacrimal opening to a nasal partition, in order to avoid hit of drug in a nasal cavity. Duration of a course of treatment is defined by the doctor.
Side effects
- increase in intraocular pressure
- a dermahemia a century, hyperaemia and a chemosis (especially at prolonged use)
- a photophobia
- tachycardia
- dryness in a mouth.
Contraindications
- glaucoma
- disturbance of urination in a benign hyperplasia of a prostate
- hypersensitivity to drug components
- children's age up to 7 years
Medicinal interactions
At use of Atropini sulfas with inhibitors of a monoaminooxidase arise disturbances of a warm rhythm, with quinine, novokainamidy – summation of cholinolytic effect is observed.
The special
instructions Appoint Atropini Sulfas follows with care taking into account the possible increased individual sensitivity to it. At administration of drug in a conjunctival sac in the form of drops it is necessary to squeeze the site of plaintive ways to prevent hit of solution to the plaintive canal and its absorption. In ophthalmologic practice it is reasonable to apply Atropini sulfas first of all with the medical purpose, and with diagnostic it is better to apply midriatik of less long action.
There are no contact lenses given about use during use of Atropini sulfas.
Pregnancy and a lactation
during pregnancy appoint drug only in urgent cases. At use of atropine during a lactation, it is necessary to stop breastfeeding, t. to drug gets into breast milk and mozhen to cause respiratory depression and drowsiness in the child.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during treatment should refrain from control of motor transport and occupations other potentially dangerous types of activity which demand the increased concentration of attention, speed of psychomotor reactions and clearness of sight.
Overdose
strengthening of side effect and development of system effects of atropine is possible: tachycardia, dryness of mucous membranes, constipations, an ischuria, emergence or strengthening of symptoms of bronchial obstruction, sweating reduction, emergence of a hyperthermia, especially at children, development of motive and mental disorders.
Treatment: intravenous administration of physostigmine 0.5-2mg (no more 5mg/day) with a speed no more than 1 mg a minute or a neostigmin of methyl sulfate intravenously 0.5-2mg or intramusculary to 0.5-1 mg is each 2-3 hours.
A form of release and packing
Eye drops 10mg/ml, a bottle of 5 ml, on 1 bottle together with the instruction for medical use in a pack.
To Store storage conditions in well corked container, in the place protected from light, at a temperature of 15 - 25 °C.
To store out of children's reach!
3 years
not to apply a period of storage after the expiration date specified on packing.
A solution period of storage after the first opening – 14 days.
Prescription status
According to the prescription
LLC GNCLS Experimental Plant Producer.
Ukraine, Kharkiv, Vorobyov St., 8.
of ATROPINI SULFAS medicine
the Trade name
Atropini sulfas
the International unlicensed
name Atropini Sulfas Dosage Form
Eye drops 10mg/ml
Structure
of 1 ml of solution contains
active agent - Atropini sulfas of 0.05 g,
excipients: sodium chloride, sodium metabisulphite, water for injections.
The description
Colourless transparent liquid
Pharmacotherapeutic group
Drugs for treatment of diseases of eyes. Midriatiki. Holinoblokatora.
ATCS01FA01 code
Pharmacological
Pharmacokinetics properties.
Considering system influence of atropine when swallowing the eye drops which got via the plaintive channel into a nasopharynx, drug is easily soaked up in digestive tract, the bioavailability of drug is 50%, elimination half-life – 13 - 38 h, atropine for 50% contacts proteins of blood plasma, is metabolized in a liver, excreted by kidneys for 50% in not changed look.
The pharmacodynamics
Atropini sulfas reduces secretion of salivary and other glands, causes tachycardia, improves atrioventricular conductivity, reduces a tone of smooth muscle bodies, is expressed expands pupils (at the same time increase in intraocular pressure is possible), causes accommodation paralysis.
The mechanism of action is caused by selective blockade by m-holinoretseptorov atropine (to a lesser extent influences N-holinoretseptory) therefore the last become insensitive to acetylcholine which is formed in the field of the terminations of postganglionic parasympathetic nerves. The maximum mydriasis comes in 30 - 40 min. and remains within 7 - 10 days, accommodation paralysis respectively in 1 - 3 h and remains 8 - 12 days.
The system effect of atropine is caused by its anticholinergic (cholinolytic) action and includes oppression of secretion salivary, gastric, bronchial, sweat glands, a pancreas, increase of warm reductions (the braking action of n.vagus decreases by heart), decrease in a tone of smooth muscle bodies (a bronchial tree, abdominal organs, etc.).
Getting through a blood-brain barrier, atropine influences the central nervous system. Drug reduces a muscle tone and a tremor at patients with parkinsonism (central cholinolytic action), atropine excites a respiratory center in therapeutic doses, high doses of atropine cause motive and mental disturbances, spasms, the hallucinatory phenomena, breath paralysis.
Indications
- diagnostic mydriasis for an eyeground research
- for achievement of paralysis of accommodation for the purpose of definition of a true refraction of an eye
- as a part of complex therapy in inflammatory diseases, injuries of an eye, an embolism or a spasm of the central artery of a retina
the Route of administration and doses
With the medical purpose to adults and children are more senior than 7 years appoint on 1 - 2 drop of atropine 2 – 3 times a day.
After instillation atropine in a conjunctival cavity it is necessary to press immediately lacrimal opening to a nasal partition, in order to avoid hit of drug in a nasal cavity. Duration of a course of treatment is defined by the doctor.
Side effects
- increase in intraocular pressure
- a dermahemia a century, hyperaemia and a chemosis (especially at prolonged use)
- a photophobia
- tachycardia
- dryness in a mouth.
Contraindications
- glaucoma
- disturbance of urination in a benign hyperplasia of a prostate
- hypersensitivity to drug components
- children's age up to 7 years
Medicinal interactions
At use of Atropini sulfas with inhibitors of a monoaminooxidase arise disturbances of a warm rhythm, with quinine, novokainamidy – summation of cholinolytic effect is observed.
The special
instructions Appoint Atropini Sulfas follows with care taking into account the possible increased individual sensitivity to it. At administration of drug in a conjunctival sac in the form of drops it is necessary to squeeze the site of plaintive ways to prevent hit of solution to the plaintive canal and its absorption. In ophthalmologic practice it is reasonable to apply Atropini sulfas first of all with the medical purpose, and with diagnostic it is better to apply midriatik of less long action.
There are no contact lenses given about use during use of Atropini sulfas.
Pregnancy and a lactation
during pregnancy appoint drug only in urgent cases. At use of atropine during a lactation, it is necessary to stop breastfeeding, t. to drug gets into breast milk and mozhen to cause respiratory depression and drowsiness in the child.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during treatment should refrain from control of motor transport and occupations other potentially dangerous types of activity which demand the increased concentration of attention, speed of psychomotor reactions and clearness of sight.
Overdose
strengthening of side effect and development of system effects of atropine is possible: tachycardia, dryness of mucous membranes, constipations, an ischuria, emergence or strengthening of symptoms of bronchial obstruction, sweating reduction, emergence of a hyperthermia, especially at children, development of motive and mental disorders.
Treatment: intravenous administration of physostigmine 0.5-2mg (no more 5mg/day) with a speed no more than 1 mg a minute or a neostigmin of methyl sulfate intravenously 0.5-2mg or intramusculary to 0.5-1 mg is each 2-3 hours.
A form of release and packing
Eye drops 10mg/ml, a bottle of 5 ml, on 1 bottle together with the instruction for medical use in a pack.
To Store storage conditions in well corked container, in the place protected from light, at a temperature of 15 - 25 °C.
To store out of children's reach!
3 years
not to apply a period of storage after the expiration date specified on packing.
A solution period of storage after the first opening – 14 days.
Prescription status
According to the prescription
LLC GNCLS Experimental Plant Producer.
Ukraine, Kharkiv, Vorobyov St., 8.
Related Products
